Galvanize Therapeutics
PrivateLast Round
Series C
Sep 3, 2025
Total Funding Raised
$218M
Company Overview
Galvanize Therapeutics operates in Healthcare & Life Sciences and is based in Redwood City, California. Its latest recorded funding round was a Series C round in September 2025.
Galvanize Therapeutics is a medical technology company that develops energy-based devices utilizing high-voltage electrical pulses to enhance biological processes for improved patient care.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Galvanize Therapeutics Comparables
Compare Galvanize Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Surgnova Healthcare Technologies | 80% | |
| AngioDynamics, Inc. | 79% | |
| HistoSonics | 78% |
For institutional investors. Book with your work email.
Galvanize Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 3, 2025 | ||||
| Series B | Sep 15, 2022 | ||||
| Series A | Mar 16, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Galvanize Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C |
| Perceptive Advisors | Series C |
| Ally Bridge Group | Series C |
| Gilmartin Capital | Series B, Series C |
| Longaeva | Series C |
| Fidelity Management & Research Company | Series C, Series B |
| Apple Tree Partners | Series B, Series C, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Senior PM hire signals market development for Aliya PEF platform.
- Sep 3, 2025
$100M round raised.
For institutional investors. Book with your work email.
Galvanize Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Galvanize Therapeutics's valuation, stock price, and market status.
Is Galvanize Therapeutics a public or private company?
Galvanize Therapeutics is a private company.
What is the current stock price of Galvanize Therapeutics?
Galvanize Therapeutics is a private company, so its shares have no public market price. Caplight tracks Galvanize Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Galvanize Therapeutics worth (valuation)?
Valuation information for Galvanize Therapeutics is not publicly available.
Can I buy Galvanize Therapeutics stock?
Galvanize Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Galvanize Therapeutics's last funding round?
Galvanize Therapeutics's most recent funding round was Series C on September 3, 2025.
Who are the main investors in Galvanize Therapeutics?
Key investors in Galvanize Therapeutics include Fidelity Management & Research Company, Apple Tree Partners, Sofinnova Partners.
Will Galvanize Therapeutics IPO soon?
No public IPO plans have been announced for Galvanize Therapeutics.
How can I track Galvanize Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Galvanize Therapeutics's shares on secondary markets.